$ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Leon Oliver Moulder Jr.
CEO
130
Employees
$23.37
Current Price
$1.12B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 3 | 6 | $2,108,128.10 | 102,845 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 3 | 9 | $3,747,128.10 | 202,845 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 11, 2026 | Lu Hongbo Director | Purchase | 25,985 | $22.50 | $584,662.50 | View Details |
| Feb 12, 2026 | Allen Patricia L Director | Purchase | 5,700 | $24.34 | $138,738.00 | View Details |
| Feb 13, 2026 | Allen Patricia L Director | Purchase | 4,160 | $26.36 | $109,657.60 | View Details |
| Feb 12, 2026 | Allen Patricia L Director | Purchase | 5,000 | $26.50 | $132,500.00 | View Details |
| Feb 12, 2026 | Allen Patricia L Director | Purchase | 5,000 | $23.77 | $118,850.00 | View Details |
| Feb 2, 2026 | MOULDER LEON O JR Director | Purchase | 57,000 | $17.96 | $1,023,720.00 | View Details |
| Jan 7, 2026 | MOULDER LEON O JR Director | Purchase | 50,000 | $16.38 | $819,000.00 | View Details |
| Jan 8, 2026 | MOULDER LEON O JR Director | Purchase | 30,000 | $16.30 | $489,000.00 | View Details |
| Jan 9, 2026 | MOULDER LEON O JR Director | Purchase | 20,000 | $16.55 | $331,000.00 | View Details |
8 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$1.00
ActualN/A
Revenue
Estimated$28.75M
ActualN/A
EPS
Estimated-$1.00
Actual-$4.54
Miss
Revenue
Estimated$13.33M
ActualN/A
EPS
Estimated-$1.22
ActualN/A
Revenue
Estimated$28.75M
ActualN/A
EPS
Estimated-$1.22
ActualN/A
Revenue
EstimatedN/A
ActualN/A
4 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$CBIO โ Crescent Biopharma, Inc.via Fairmount Funds Management LLC$VRDN โ Viridian Therapeutics, Inc.\DEvia Fairmount Funds Management LLC$COGT โ Cogent Biosciences, Inc.via Fairmount Funds Management LLC$MANE โ Veradermics, Incorporatedvia ENRIGHT PATRICK G$VERA โ Vera Therapeutics, Inc.via ENRIGHT PATRICK G